Podcasts about therapies

Send us Fan MailWhat would it really mean to shorten neonatology fellowship training to two years? In this episode, Ben and co-host Dr. Shetal Shah sit down with three division heads, Dr. Jill Maron (Brown), Dr. Patrick McNamara (University of Iowa), and Dr. Sarah Taylor (Yale), to examine the ABP's proposed changes from the perspective of those who run major academic NICUs. From the operational and financial strain of losing an entire class of third-year fellows, to the erosion of scholarly development, dwell time, and faculty wellbeing, the conversation makes clear that the costs of this proposal go far deeper than the curriculum. How do you staff an 80-bed NICU without junior fellows? Who funds the gap? And what happens to the next generation of academic neonatologists if we train them in isolation from the very experiences that shape their identity as clinicians and scholars?Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Discover how insulin potentiation therapy and hyperthermia offer low-toxicity cancer treatment by boosting drug delivery and immunity. #Hyperthermia #IPT #GentleCancerCare #HealthTalks

rWotD Episode 3333: Expressive therapies continuum Welcome to random Wiki of the Day, your journey through Wikipedia's vast and varied content, one random article at a time.The random article for Friday, 19 June 2026, is Expressive therapies continuum.The Expressive Therapies Continuum (ETC) is a model of creative functioning used in the field of art therapy that is applicable to creative processes both within and outside of an expressive therapeutic setting. The concept was initially proposed and published in 1978 by art therapists Sandra Kagin and Vija Lusebrink, who based the continuum on existing models of human development and information processing.This schematic model serves to describe and assess an individual's level of creative functioning based on aspects such as the artist's purpose for creating a piece, choice of medium, interaction with the chosen medium, and imagery within the piece. Conversely, it also serves to meet the needs of the client by assisting the art therapist in choosing a developmentally or situationally appropriate activity or art medium. By analyzing an individual's art making process and the resulting artwork using the ETC, art therapists can assess strengths, weaknesses, and disconnect in various levels of a client's cognitive functioning - suggesting or substantiating diagnosis of, or recovery from, a mental health condition.This recording reflects the Wikipedia text as of 01:07 UTC on Friday, 19 June 2026.For the full current version of the article, see Expressive therapies continuum on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Bluesky at @wikioftheday.com.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm generative Kajal.

Awakening the Future: How Emerging Narcolepsy Type 1 Therapies Are Redefining Care and Expectations On this episode guest host Steve Kheloussi, PharmD, MBA, FAMCP, principal consultant at Kheloussi Consulting, speaks with Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA, FAMCP, founder and CEO of LoneStar Health Solutions, about the evolving treatment landscape for narcolepsy. The discussion explores the burden of delayed diagnosis, the real-world impact of excessive daytime sleepiness and cataplexy, and how treatment may shift from symptom management toward addressing the underlying disease process. Steve and Amy also examine formulary considerations, patient-reported outcomes, utilization management challenges, and how managed care organizations can balance access, value, and patient-centered care as new therapies enter the market. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

What if curing disease came down to better directions?This week on Discovery Matters, we're talking viral vectors, AI, and why delivery is the unsung hero of gene therapy. Dr. Lijia Ma joins us to explain how scientists are engineering biological “postmen” to find new destinations beyond the liver — including the brain — and why timing matters just as much as location.With insights from Cytiva's Peiqing Zhang, we explore how advanced biology, data science, and biomanufacturing all collide to turn promising therapies into real-world treatments.

When we first featured a guest discussing GLP-1 therapies, the public's understanding of these drugs to treat obesity was still developing. In 2023, our expert was Dr. Jamy Ard, the then-incoming president of The Obesity Society. Even then, Dr. Ard was stressing that more choices would lower prices for consumers. We look back on that […] The post GLP-1 Therapies: Where We've Been & Where We're Going appeared first on Healthy Communities Online.

Do you know how tumor-agnostic therapies are helping to reshape cancer treatment pathways? Credit available for this activity expires: 6/16/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?ecd=bdc_podcast_libsyn_mscpedu

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

Send us Fan MailWhat does it mean to truly improve outcomes for very low birth weight infants, and are we actually doing it? In this episode, Daphna sits down with Dr. Joseph Kaempf, neonatologist and Medical Director of Value Research and Innovation at Providence Health System in Oregon, to examine some uncomfortable truths about neonatal quality improvement. Dr. Kaempf shares findings from a study spanning 16 NICUs over 14 years showing that composite morbidity outcomes have remained flat while length of stay has increased. He explores why traditional QI tools like driver diagrams and PDSA cycles may no longer be sufficient, and why augmented intelligence may be the next frontier. The conversation also touches on culture as a driver of NICU performance and the gap between institutional interests and true shared decision-making with families. A candid episode for anyone invested in the future of neonatology.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Oser la Reconversion, le Podcast numéro 1 sur la Reconversion, épisode #199 ** Masterclass gratuite avec Clervie Rose le 25 juin à 20h pour retrouver une carrière alignée. Inscris-toi ici : https://www.oserlareconversion.fr/masterclass-juin-2026 **** Réserve ton coaching gratuit de 30 minutes ici pour faire le point sur ta vie pro : https://www.oserlareconversion.fr/appel/ **Aujourd'hui, j'accueille dans Oser la Reconversion, Raphaëlle Giacomini-Agostini. Ancienne ingénieur en IA pendant 20 ans, Raphaëlle est devenue psy. Elle est très active sur les réseaux sociaux sous le pseudo @les_therapies_de_raphaellePetite, Raphaëlle rêvait déjà d'être psy. Mais ses parents lui avaient dit les psy sont fous ! Raphaëlle s'oriente donc dans une carrière d'ingénieur en IA. La seule fille dans sa classe. En parallèle, elle suit des cours de yoga et lit des livres de psycho car elle a besoin de sens et de spiritualité.C'est à 40 ans que Raphaëlle fait une crise de la quarantaine. Elle divorce et se lance dans des études de psy. Raphaëlle est spécialisée sur la relation à soi et à l'autre notamment spécialisée en psy Gestalt, EMDR, therapie de couple. Elle exerce depuis 15 ans.Retrouvez Oser la Reconversion sur Instagram : https://www.instagram.com/oserlareconversion/Télécharger le cahier d'exercices d'Oser la Reconversion pour se reconvertir : https://www.oserlareconversion.fr/newsletterNotes & Références : - Instagram de Raphaëlle : https://www.instagram.com/les_therapies_de_raphaelle/- Site internet de Raphaëlle : https://www.lestherapiesderaphaelle.com/- Prendre Rdv avec Raphaëlle : https://www.lestherapiesderaphaelle.com/contact- Linkedin de Raphaëlle : https://www.linkedin.com/in/raphaellega/Contactez-moi ! Si le Podcast vous plait, le meilleur moyen de me le dire, ou de me faire vos feedbacks (et ce qui m'aide le plus à le faire connaître), c'est simplement de laisser un avis sur Apple Podcast, un commentaire sur Youtube et d'en parler autour de vous. ça m'aide vraiment alors n'hésitez pas.Pour me poser des questions, participer au podcast ou suivre mes aventures, c'est par ici :- Sur Instagram @clervierose : https://www.instagram.com/oserlareconversion et @clervierose : https://www.instagram.com/clervierose- Sur Linkedin : https://www.linkedin.com/in/clervie-rose-boennec-a09065102/- Sur Youtube https://www.youtube.com/channel/UC7Qzm4HrS5OdmdXoY344vqA- Par mail : partenariats@oserlareconversion.fr

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUS865. CME/MOC/NCPD/AAPA/ASWB-ACE/CDR/APA/IPCE credit will be available until June 17, 2027.Lighting the Way to Patient-Centered Alzheimer's Care: Employing Amyloid-Targeting Therapies Safely and Effectively Through Careful Patient Selection and Shared Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Gerontological Society of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Pour écouter l'épisode en entier, tapez #199 Raphaëlle, disponible le 15 juin** Masterclass gratuite avec Clervie Rose le 25 juin à 20h pour retrouver une carrière alignée. Inscris-toi ici : https://www.oserlareconversion.fr/masterclass-juin-2026 **** Réserve ton coaching gratuit de 30 minutes ici pour faire le point sur ta vie pro : https://www.oserlareconversion.fr/appel **

Send us Fan MailPhototherapy duration, jaundice and UTIs, extended CPAP, and The Pitt. A full week on the Incubator Journal Club.Ben opens with a nationwide Swedish cohort study from JAMA Network Open examining phototherapy duration in nearly 5,000 very preterm infants. Longer phototherapy was not significantly associated with late neonatal mortality, but six to seven days was associated with significantly higher rates of severe neonatal morbidity. With 95% of the cohort receiving phototherapy, Ben and Daphna question how much evidence actually supports the near-universal practice.Daphna follows with a retrospective study from Istanbul showing that 31% of term and near-term neonates hospitalized for unexplained hyperbilirubinemia had culture-proven UTIs, with pathological renal ultrasound findings independently associated with a 4.6-fold increased odds of UTI.Ben then reviews the extended CPAP secondary analysis by Mamidi and McEvoy, showing that two additional weeks of bubble CPAP reduced intermittent hypoxemia episodes from 151.7 to 57.6 compared to discontinued CPAP.Daphna closes with the NEOASP five-day UTI treatment guideline from Nationwide Children's Hospital, where a structured stewardship approach yielded a 1% failure rate.Ben and Eli close the week reflecting on The Pitt and what it reveals about the broken realities of American healthcare.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this episode of Neo News, Ben and Eli discuss the cultural phenomenon of HBO Max's new hit medical drama, The Pitt. Sparked by an insightful critique in The New Yorker by Dr. Dhruv Khullar, they dive into why this Noah Wyle-led series is capturing the attention of millions of Americans, including healthcare workers and patients alike. They explore how the show's unflinching portrayal of systemic failures, from ER overcrowding to uninsured patients leaving against medical advice, mirrors their daily reality in the hospital. Tune in as they discuss whether the shared humanity seen on screen can bridge the gap between doctors and patients or simply highlight the exhausting "pit" of modern medicine!----The Pitt: https://www.newyorker.com/culture/the-lede/what-the-pitt-taught-me-about-being-a-doctorSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

We love to hear from our listeners. Send us a message.In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability before they become mainstream, and why the field must move beyond proof of concept to reproducible clinical performance across patients and diseases. He discusses the importance of patient selection, tissue specificity, and matching editing efficiency to biological thresholds, and much more. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

In this episode of PsychCrunch, join our host, Tabby Taylor Buck, as she explores cutting-edge and historical approaches to voice hearing therapies. Come along for an insider look at the hallucination-mimicking AVATAR2 trial as Tabby sits down with Trial Coordinator Dr Clementine Edwards, then take a tour of the Mental Health Museum in Wakefield with her, Museum Curator Jane Stockdale, and Museum Officer Sally Evans. Learn what it's like to hear voices from Dr Andrew Grundy (Lived Experience Researcher, Manchester University), and what exactly schizophrenia, voice hearing, and psychosis mean with Dr Chris Taylor (University of Sheffield). This is Episode 47 of PsychCrunch, the podcast of the British Psychological Society's Research Digest, sponsored by Zanda. Episode Credits: Hosted by Tabby Taylor Buck. Audio wizardry by Jeff Knowler. Edited by Emma Barratt. Produced by Tabby Taylor Buck. Hungry for more? Check out this piece from Ben Gray, Peer Support Worker at EPUT (Essex Partnership University NHS Foundation Trust), in which he gives a unique account of how hearing voices support sessions can provide inspiration and hope. Or head over to The Psychologist and explore. We're always interested in hearing from you. If you'd like to get in touch, you can find us on BlueSky @ResearchDigest. PsychCrunch is brought to you by Zanda, the all-in-one practice management software designed for psychologists. With telehealth, easy mobile access, and automated tools, including online scheduling and reminders, Zanda helps you run your practice, your way. Find out more at ZandaHealth.com 

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Send us Fan MailIs five days of antibiotics enough to treat a urinary tract infection in a NICU infant? In this Journal Club episode, Ben and Daphna review a single-center study from Nationwide Children's Hospital examining adherence and safety of a five-day antibiotic treatment guideline for culture and urinalysis-proven UTIs in the NICU. Among 77 infants with 93 bacterial UTIs, the five-day course was associated with a 1% failure rate, defined as reinitiation of antibiotics within seven days for the same organism. The episode also explores the potential role of enteral antibiotic therapy and what shorter treatment courses could mean for babies still weeks away from discharge.----Urinary tract infection in the neonatal intensive care unit. Magers J, Burton A, Prusakov P, White NO, Miller RR, Moraille R, Theile AR, Sánchez PJ; Nationwide Children's Hospital Neonatal Antimicrobial Stewardship Program (NEO-ASP).J Perinatol. 2026 May;46(5):754-760. doi: 10.1038/s41372-026-02690-1. Epub 2026 Apr 29.PMID: 42056240 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailWhat happens to intermittent hypoxemia when you keep a stable preterm infant on CPAP for two extra weeks? In this Journal Club episode, Ben and Daphna review a secondary analysis from the Journal of Pediatrics by Mamidi and McEvoy. Among 95 infants randomized to either two additional weeks of bubble CPAP on room air or discontinued CPAP, those in the extended CPAP group experienced significantly fewer intermittent hypoxemia episodes (57.6 versus 151.7), higher baseline saturations, and greater functional residual capacity. The episode also touches on the practical implications for units navigating oral feeding protocols alongside extended CPAP.----Extended Continuous Positive Airway Pressure in Infants Born Preterm Decreases Intermittent Hypoxemia: A Secondary Analysis of a Randomized Controlled Trial. Mamidi RR, Go MDA, Harris J, Olson M, Milner K, Tepper RS, Morris C, Park B, Schelonka R, MacDonald KD, McEvoy CT.J Pediatr. 2026 May 25:115165. doi: 10.1016/j.jpeds.2026.115165. Online ahead of print.PMID: 42190903Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this Journal Club episode, Daphna reviews a retrospective cohort study from Istanbul examining clinical, laboratory, and ultrasound factors associated with UTI in neonates hospitalized for unexplained hyperbilirubinemia. Among 96 term and near-term infants, 31% had culture-proven UTIs, a striking prevalence. Pathological renal ultrasound findings were independently associated with UTI, with affected neonates 4.6 times more likely to have a concurrent infection. Notably, standard laboratory markers including CRP and white blood cell count failed to distinguish UTI-positive from UTI-negative infants. The findings prompt a practical question: should urine culture be part of the routine workup for neonatal hyperbilirubinemia?----Renal ultrasonography findings are associated with urinary tract infection in neonates with asymptomatic hyperbilirubinemia. Sarı EE, Salihoğlu Ö.J Perinatol. 2026 Apr 13. doi: 10.1038/s41372-026-02686-x. Online ahead of print.PMID: 41975209Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Send us Fan MailIn this Journal Club episode, Ben and Daphna review a nationwide Swedish cohort study examining the association between phototherapy duration and neonatal outcomes in very preterm infants (22 to 31 weeks). The study's primary outcome, late neonatal mortality on days 8 to 27, was not significantly associated with phototherapy duration. However, longer phototherapy exposure was associated with increased odds of severe neonatal morbidity, including IVH and BPD, in infants born at 26 to 31 weeks. The findings prompt an important conversation about the near-universal use of phototherapy in preterm neonates and whether current practice warrants reassessment.----Phototherapy, Morbidity, and Mortality in Very Preterm Newborns. Deschmann E, Håkansson S, Söderling J, Norman M.JAMA Netw Open. 2026 May 1;9(5):e2614107. doi: 10.1001/jamanetworkopen.2026.14107.PMID: 42166159 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

On this episode of SurgOnc Today, Dr. Amanda Kirane and Dr. Allison Betof discuss the clinical application of TIL therapy for melanoma patients, including the comprehensive care and teamwork required. They also discuss lessons learned and newer clinical trials optimizing the therapy.

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

Description:  How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.           Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.  This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.  Thank you to Lilly for their support of this program activity.  Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.  (1:35)  What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss. (3:29)  Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis. (5:23)  The metabolic, cardiovascular, and psoriatic disease convergence. (7:19)  Will reduction of inflammation impact cardiovascular risk? (10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese. (13:45)  Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis. (17:06)  Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1                receptor agonist therapy. (19:07)  Having the conversation of adding a GLP-1 RA medication to a treatment regimen. (22:40)  The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways. Key Takeaways: ·       Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.   ·       Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.   ·       The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.   Guest Bios: Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.  Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Resources: "The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan   "NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release "Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger. 

Send us Fan MailWhat if closing a PDA could be done at the bedside in under 10 minutes, without transporting a fragile preterm infant to the cath lab? Dr. Shyam Sathanandam, Chief of Cardiovascular Medicine at Nicklaus Children's Heart Institute, joins us to discuss the evolution of transcatheter PDA closure in extremely preterm infants. We cover how bedside procedures protect the most vulnerable neonates, which infants are most likely to benefit from closure, the learning curve and complication profile, and Dr. Sathanandam's vision of eventually training neonatologists to perform this procedure themselves.Dr. Shyam Sathanandam has consulting and compensation relationships with Abbott Laboratories and Medtronic, both relevant to topics discussed in this episode.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

0:00 Intro2:00 New US Executive Order Accelerates Drug Therapies (White House / FDA)28:00 End/Final ThoughtsDale Johnson's Podcast about Psychedelics and Presidential OrdersTruth in Love Episode 569:https://biblicalcounseling.com/resource-library/podcast-episodes/psychedelics-and-presidential-orders/Stream the video library for the addiction counselor.COUNSEL — https://theaddictionconnection.thinkific.com/

Send us Fan MailOpioid withdrawal dosing, intranasal breast milk, human milk fortification in Japan, neonatal dysphagia, and vaccine policy. A full week on the Incubator Journal Club.Ben opens with the Optimized NOW trial in JAMA: symptom-based dosing reduced time to medical readiness for discharge by nearly two and a half days in NOWS infants managed with Eat Sleep Console, and allowed 65% of pharmacologically treated infants to avoid scheduled opioids entirely.Daphna reviews a small RCT out of Turkey showing improved cerebral oxygenation and favorable vital sign trends after intranasal breast milk administration in preterm infants, adding to the growing tolerability data for this intervention.Ben then covers the JASMINE trial, a Phase 3 RCT in Japan showing significantly better weight gain velocity with an exclusive human milk diet in very low birth weight infants.Daphna closes with a retrospective cohort study on FEES-confirmed dysphagia in preterm infants. Of those who met criteria for evaluation, every single one had laryngeal penetration and 57% were aspirating.Ben and Eli close the week on the quiet dismantling of vaccine infrastructure in the US and what it means for the populations in your NICU.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this fast-paced episode of Neo News, Eli and Ben tackle the rapidly shifting landscape of vaccine regulation and economics in the US. They discuss recent political maneuvers surrounding the Vaccine Injury Compensation Program (VICP) and how expanding liability could quietly push manufacturers out of the market entirely. The hosts also examine the FDA's recent hesitation to review Moderna's new mRNA flu vaccine, highlighting how these administrative roadblocks threaten the financial viability of developing novel vaccines—including critical immunizations for pediatric and neonatal populations. Tune in for a sharp analysis of how top-down policy changes might reshape everyday clinical practice!----1) https://thehill.com/policy/healthcare/5689850-kennedy-dismisses-vaccine-advisors/2) https://www.washingtonpost.com/opinions/2026/01/15/rfk-jr-vaccines-autism-vicp/3) https://www.nytimes.com/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html4) https://www.nytimes.com/2026/02/16/health/rfk-vaccine-manufacturers.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Marlene Geren, RN BSN & Chris Lezu, PA-C from BWEll4EVER Labs and IV Therapies! I have used them for lab work AND for IV therapy when I am not feeling well and/or pain! Find out more at: www.beginwithlabs.com ===== THANK YOU TO OUR SPONSORS: (Welcome to our NEW sponsor) Signal Investigations: https://www.signalpi.com/ Nutrition World: https://nutritionw.com/ Vascular Institute of Chattanooga: https://www.vascularinstituteofchattanooga.com/ The Barn Nursery: https://www.barnnursery.com/ Optimize U Chattanooga: https://optimizeunow.com/chattanooga/ Guardian Investment Advisors: https://giaplantoday.com/ Alchemy Medspa and Wellness Center: http://www.alchemychattanooga.com/ Our House Studio: https://ourhousestudiosinc.com/ Team Montieth Real Estate - Lori Montieth: https://www.findchattanoogarealestate.com/ Ballinger and Associates - Risk Management: https://ballingerandassociates.com/ AirSpace Acoustics: https://www.airspaceacoustics.com/ BWELL4EVER: Labs and IV Therapies: https://www.bwell4ever.org/ ALL THINGS JEFF STYLES: www.thejeffstyles.com PART OF THE NOOGA PODCAST NETWORK: www.noogapodcasts.com Please consider leaving us a review on Apple and giving us a share to your friends! This podcast is powered by ZenCast.fm

Send us Fan MailHow often are we missing dysphagia in our most vulnerable NICU patients? In this episode of Journal Club, Daphna reviews a retrospective cohort study from the Journal of Perinatology examining the incidence and risk factors of dysphagia confirmed by flexible endoscopic evaluation of swallowing (FEES) in very preterm and very low birth weight infants. Among infants showing persistent feeding difficulties at 38 weeks post-menstrual age, laryngeal penetration was detected in all infants who underwent FEES, and tracheal aspiration in nearly 60%. Ben and Daphna discuss whether we are naming dysphagia for what it is, whether earlier instrumental assessment could change outcomes, and what it means for families to finally understand why their baby is struggling to feed.----Incidence and factors associated with dysphagia in infants born very preterm or very low birth weight. Reynolds J, Suterwala M, Desai S, Chiruvolu A.J Perinatol. 2026 Apr 29. doi: 10.1038/s41372-026-02701-1. Online ahead of print.PMID: 42056238Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailJapan has some of the best survival rates for extremely preterm infants in the world, yet feeding practices there look very different from what many of us are used to. In this episode of Journal Club, Ben reviews the JASMINE trial, a multicenter phase three randomized controlled trial evaluating an exclusive human milk diet compared to a standard cow milk-based diet in very low birth weight infants in Japan. Infants on an exclusive human milk diet gained weight significantly faster, reached full feeds six days sooner, and had fewer antibiotic days. Ben then sits down with first author Professor Katsumi Mizuno and Dr. Melinda Elliott, CMO of Prolacta Bioscience, to discuss the backstory and broader implications of this landmark trial.---Growth and safety evaluation in very low birth weight infants receiving an exclusive human milk diet: a phase III randomized control trial in Japan. Mizuno K, Miyazawa T, Kondo U, Nishikubo T, Yamamoto Y, Nakano Y, Hiroma T, Ikeda K, Murase M, Jimi H, Hokuto I, Miyata M.J Perinatol. 2026 Apr 27. doi: 10.1038/s41372-026-02695-w. Online ahead of print.PMID: 42045666Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailWhat does it take to turn a single struggling baby into a national standard of care? In this episode, Ben sits down with Professor Katsumi Mizuno (Showa Medical University) and Dr. Melinda Elliott (Chief Medical Officer, Prolacta Bioscience) to discuss the landmark Jasmine Trial, the first randomized controlled trial of an exclusive human milk diet (EHMD) in Japan. The results: significantly better weight and length gain, fewer antibiotic days, and improved feeding tolerance in very preterm infants. After an eight-year regulatory journey, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) granted Prolacta's human milk-based fortifier PrimiFort drug-level designation, a global first, ensuring equitable, nationally reimbursed access for every preterm infant in the country. The conversation also looks ahead to the Fuji Trial and what Japan's precedent-setting decision could mean for Europe and the US.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!